Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.

Sabbe R, Picchio GR, Pastore C, Chaloin O, Hartley O, Offord R, Mosier DE.

J Virol. 2001 Jan;75(2):661-71.

2.

Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy.

Picchio GR, Valdez H, Sabbe R, Landay AL, Kuritzkes DR, Lederman MM, Mosier DE.

J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):289-95.

PMID:
11114828
3.

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PW, Mosier DE, Burton DR.

Immunity. 1999 Apr;10(4):431-8.

4.

Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA, Wilken J.

J Virol. 1999 May;73(5):3544-50.

5.
6.

Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co-infection.

Picchio GR, Nakatsuno M, Boggiano C, Sabbe R, Corti M, Daruich J, PĂ©rez-Bianco R, Tezanos-Pinto M, Kokka R, Wilber J, Mosier D.

J Med Virol. 1997 Jun;52(2):219-25.

PMID:
9179772
7.

Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines.

Rochford R, Cannon MJ, Sabbe RE, Adusumilli K, Picchio G, Glynn JM, Noonan DJ, Mosier DE, Hobbs MV.

Viral Immunol. 1997;10(4):183-95.

PMID:
9473149

Supplemental Content

Support Center